# Memantine - Communication Study

> **NCT00624026** · PHASE3 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 107 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Memantine-HCl

## Key facts

- **NCT ID:** NCT00624026
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2011-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624026, "Memantine - Communication Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00624026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*